<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Covid</title>
    <link href="https://fonts.googleapis.com/css2?family=Montserrat:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="main.css">
</head>
<body>

    <div class="header">
        CORRESPONDENCE
        <span class="label">| Nov 13, 2024 | <span class="free">FREE</span></span>
    </div>

    <div class="image">
        <img src="images/chatyy.jpg" alt="Research chart" />
    </div>

    <h1>Activity of Research-Grade Pemivibart against SARS-CoV-2 Sublineages</h1>
    <h2>Q. Wang and Others</h2>

    <p class="body">
        SARS-CoV-2 continues to evolve under immunologic pressure. A
        synthesized version of pemivibart, an antiâ€“SARS-CoV-2 monoclonal
        antibody with recent emergency-use authorization, showed mixed
        activity against emerging variants.
    </p>

    <p class="correction">
        <strong>Correction</strong>
        <a href="#">Pemivibart Activity against Recent SARS-CoV-2 JN.1 Sublineages</a>
    </p>

</body>
</html>